Jae Jung Lee, Jung Han Yoon, Sang Jin Kim, Han Soo Yoo, Seok Jong Chung, Yang Hyun Lee, Suk Yun Kang, Hae-Won Shin, Sook Keun Song, Jin Yong Hong, MunKyung Sunwoo, Ji Eun Lee, Jong Sam Baik, Young H Sohn, Phil Hyu Lee
The aim of this trial was to investigate the safety, tolerability, and capability of serum uric acid (UA) elevation of inosine 5'-monophosphate (IMP) in multiple system atrophy (MSA). The IMPROVE-MSA trial was a randomized, double-blind, placebo-controlled trial in patients with MSA with no history of hyperuricemia-related disorders. The participants were assigned to placebo (n = 25) or IMP (n = 30) in a 1 to 1 ratio, and then followed up for 24 weeks. The primary end points included safety, tolerability, and alteration of the serum UA level during the follow-up period...
May 2021: Clinical Pharmacology and Therapeutics